JavaScript NENÍ povolen !

Prosím povolte JavaScript.

* Zobrazit nápovědu

Reset

MeSH: pocení

51 záznamů v PubMed Filtry

Článek

Questions and questionnaires about acute climacteric syndrome

Casopis lekaru ceskych. 2024 ; 162 (7-8) : 337-343.

Cas Lek Cesk
ISSN 0008-7335
Zdroj

The acute climacteric syndrome has a large scale of symptoms. Main symptoms are hot flashes and night sweats. Each symptom could be presented alone or commonly in combination with other symptoms. The acute climacteric syndrome is induced by decrease and fluctuations of estrogen and neurosteroids levels. Therapy could be focused on hormone replacement. Changes of quality of life and especially effects of the therapy could be measured by standardized questionaries.

Klíčová slova
climacteric, genetics, hot flushes, quality of life,
MeSH
klimakterium fyziologie MeSH
kvalita života MeSH
lidé MeSH
menopauza fyziologie MeSH
návaly * MeSH
pocení fyziologie MeSH
průzkumy a dotazníky MeSH
syndrom MeSH
Check Tag
lidé MeSH
ženské pohlaví MeSH
Publikační typ
časopisecké články MeSH
přehledy MeSH

Článek

Emerging toxicity of 5,6-methylenedioxy-2-aminoindane (MDAI): Pharmacokinetics, behaviour, thermoregulation and LD50 in rats

Progress in neuro-psychopharmacology & biological psychiatry. 2016 Aug 01 ; 69 () : 49-59. [epub] 20160412

Prog Neuropsychopharmacol Biol Psychiatry
ISSN 1878-4216 | 0278-5846
Zdroj

MDAI (5,6-Methylenedioxy-2-aminoindane) has a reputation as a non-neurotoxic ecstasy replacement amongst recreational users, however the drug has been implicated in some severe and lethal intoxications. Due to this, and the fact that the drug is almost unexplored scientifically we investigated a broad range of effects of acute MDAI administration: pharmacokinetics (in sera, brain, liver and lung); behaviour (open field; prepulse inhibition, PPI); acute effects on thermoregulation (in group-/individually-housed rats); and systemic toxicity (median lethal dose, LD50) in Wistar rats. Pharmacokinetics of MDAI was rapid, maximum median concentration in serum and brain was attained 30min and almost returned to zero 6h after subcutaneous (sc.) administration of 10mg/kg MDAI; brain/serum ratio was ~4. MDAI particularly accumulated in lung tissue. In the open field, MDAI (5, 10, 20 and 40mg/kg sc.) increased exploratory activity, induced signs of behavioural serotonin syndrome and reduced locomotor habituation, although by 60min some effects had diminished. All doses of MDAI significantly disrupted PPI and the effect was present during the onset of its action as well as 60min after treatment. Unexpectedly, 40mg/kg MDAI killed 90% of animals in the first behavioural test, hence LD50 tests were conducted which yielded 28.33mg/kg sc. and 35mg/kg intravenous but was not established up to 40mg/kg after gastric administration. Disseminated intravascular coagulopathy (DIC) with brain oedema was concluded as a direct cause of death in sc. treated animals. Finally, MDAI (10, 20mg/kg sc.) caused hyperthermia and perspiration in group-housed rats. In conclusion, the drug had fast pharmacokinetics and accumulated in lipohilic tissues. Behavioural findings were consistent with mild, transient stimulation with anxiolysis and disruption of sensorimotor processing. Together with hyperthermia, the drug had a similar profile to related entactogens, especially 3,4-metyhlenedioxymethamphetamine (MDMA, ecstasy) and paramethoxymethamphetamine (PMMA). Surprisingly subcutaneous MDAI appears to be more lethal than previously thought and its serotonergic toxicity is likely exacerbated by group housing conditions. MDAI therefore poses greater risks to physical and mental health than recognised hitherto.

Klíčová slova
5,6-methylenedioxy-2-aminoindane, Body temperature, Locomotion, MDAI, Median lethal dose, Open field, Pharmacokinetics, Prepulse inhibition, Sensory gating, Toxicology, Wistar rat,
MeSH
habituace (psychofyziologie) účinky léků MeSH
indany aplikace a dávkování farmakokinetika farmakologie toxicita MeSH
LD50 MeSH
mozek účinky léků MeSH
myokard patologie MeSH
pocení účinky léků MeSH
pohybová aktivita účinky léků MeSH
potkani Wistar MeSH
prepulsní inhibice účinky léků MeSH
psychotropní léky aplikace a dávkování farmakokinetika farmakologie toxicita MeSH
serotoninový syndrom chemicky indukované MeSH
sliny účinky léků MeSH
srdce účinky léků MeSH
termoregulace účinky léků MeSH
zvířata MeSH
Check Tag
mužské pohlaví MeSH
zvířata MeSH
Publikační typ
časopisecké články MeSH
práce podpořená grantem MeSH
Názvy látek
5,6-methylenedioxy-2-aminoindane MeSH Prohlížeč
indany MeSH
psychotropní léky MeSH

Článek

Physiological differences for distinct somatic sensory modalities and sweating among the donor sites of cutaneous and fasciocutaneous free flaps

Acta chirurgiae plasticae. 2000 ; 42 (1) : 7-12.

Acta Chir Plast
ISSN 0001-5423
Zdroj

Differences of sensation and sweating among the typical sites of cutaneous and fasciocutaneous flaps (scapular, lateral arm, radial forearm, groin and dorsalis pedis) were assessed in 30 healthy volunteers (20 males and 10 females) aged 17-62 years (mean 38.2 years). Standard clinical methods were used: Semmes-Weinstein monofilaments for testing light touch threshold, discriminator and blunt caliper for evaluation of static and dynamic two-point discrimination and the Marstock quantitative method for assessing the normative values of warm-cold difference limen and heat and cold pain thresholds. Spontaneous sweat secretion was observed and documented by the ninhydrin test. We established various physiological differences for distinct somatic sensory modalities and sweating among the body regions (donor sites of cutaneous and fasciocutaneous free flaps).